Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAVERS: Colesevelam for PFAS Reduction in Veterans
NCT07592858Phase 2Not yet recruiting
- Sponsor
- University of Rhode Island
- Start
- Jul 2026
- Primary completion
- Apr 2029
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of colesevelam in hyperlipidemia, sponsored by University of Rhode Island. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
colesevelam
03
Conditions
hyperlipidemia
Beyond the preview
Go deeper on NCT07592858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07592858.